<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03455452</url>
  </required_header>
  <id_info>
    <org_study_id>CA209-9GY</org_study_id>
    <nct_id>NCT03455452</nct_id>
  </id_info>
  <brief_title>Non-Interventional Study (NIS) of Nivolumab With or Without Ipilimumab in Participants With Advanced Kidney Cancer</brief_title>
  <acronym>WITNESS</acronym>
  <official_title>A National, Prospective, Non-Interventional Study (NIS) of Nivolumab (BMS-936558) With or Without Ipilimumab (BMS-734016) in Patients With Advanced Renal Cell Carcinoma in Real Life Setting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a French, nationwide, prospective, observational, multi-center study in participants&#xD;
      diagnosed with advanced renal cell carcinoma, who start a new systemic therapy with nivolumab&#xD;
      with or without ipilimumab for the first time and within the market authorization approval.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 21, 2018</start_date>
  <completion_date type="Anticipated">March 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>By Cohort</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Overall Response Rate (BORR)</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Overall Response (BOR)</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of socio-demographic characteristics of participants</measure>
    <time_frame>Approximately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of clinical characteristics of participants</measure>
    <time_frame>Approximately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of management of participants with treatment-related adverse events (AEs)</measure>
    <time_frame>Approximately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of management of participants according to Memorial Sloan Kettering Cancer Center (MSKCC) score</measure>
    <time_frame>At baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of management of participants according to International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) score</measure>
    <time_frame>At baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of treatment patterns in participants with advanced Renal Cell Carcinoma (RCC)</measure>
    <time_frame>Approximately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of incidence of AEs</measure>
    <time_frame>Approximately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of Severity of AEs</measure>
    <time_frame>Approximately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of management of AEs</measure>
    <time_frame>Approximately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life of participants using Functional Assessment of Cancer Therapy -Kidney Symptom Index (FKSI-19) questionnaires</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>The FKSI-19 will be graded by the patient on a scale from 0 to 4 (range &quot;not at all to very much&quot;)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life of participants using European Quality of Life-5 Dimensions (EQ-5D) questionnaires</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>The EQ-5D descriptive system consists of 5 dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression, each with 3 levels (eg, no problems, moderate problems, extreme problems)</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Renal Cell Carcinoma</condition>
  <condition>Renal Cell Cancer</condition>
  <condition>Adenocarcinoma Of Kidney</condition>
  <condition>Adenocarcinoma, Renal Cell</condition>
  <condition>Kidney Cancer</condition>
  <condition>Cancer of the Kidney</condition>
  <arm_group>
    <arm_group_label>Cohort 1: Nivolumab</arm_group_label>
    <description>Participants diagnosed with advanced renal cell carcinoma (RCC) and whose physician has decided to initiate a treatment with Nivolumab for the first time for the treatment of RCC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Nivolumab + Ipilimumab</arm_group_label>
    <description>Participants diagnosed with advanced RCC and whose physician has decided to start a new systemic therapy with nivolumab + ipilimumab for the first time for the treatment of RCC</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Adult participants who are at least 18 of age at the time of the treatment decision with&#xD;
        the diagnosis of advanced renal cell cancer (RCC) (histologically or cytologically&#xD;
        confirmed) and whose physician has already decided to initiate a treatment with nivolumab&#xD;
        or with nivolumab plus ipilimumab for the first time for the treatment of RCC, according to&#xD;
        the label approved in France.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        -Adult participants with the diagnosis of advanced renal cell cancer (RCC) (histologically&#xD;
        or cytologically) whose physician has already decided to initiate a treatment with&#xD;
        nivolumab with or without ipilimumab for the first time for the treatment of RCC, according&#xD;
        to the label approved in France&#xD;
&#xD;
        NOTE: Nivolumab with ipilimumab is indicated for the first-line treatment of adult&#xD;
        participants with intermediate/poor-risk advanced RCC&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Primary diagnosis of a cancer other than advanced RCC within the past five years, ie,&#xD;
             a cancer other than RCC that requires systemic or other treatment&#xD;
&#xD;
          -  Previously treated with anti-PD1, anti-programmed death-ligand 1 (anti-PDL1) or&#xD;
             anti-CTLA4 therapy&#xD;
&#xD;
          -  Currently included in an interventional clinical trial for advanced or RCC.&#xD;
             Participants who have completed participation in an interventional trial; or who are&#xD;
             not receiving study drug anymore and who are only followed-up for overall survival&#xD;
             (OS) can be enrolled&#xD;
&#xD;
          -  Pregnant women and participants under guardianship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information,</last_name>
    <phone>please email:</phone>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT # and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Paris</city>
        <zip>75002</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Paris</city>
        <zip>75002</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0001</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 21, 2018</study_first_submitted>
  <study_first_submitted_qc>February 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2018</study_first_posted>
  <last_update_submitted>February 23, 2021</last_update_submitted>
  <last_update_submitted_qc>February 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

